Shock wave therapy is a non-invasive treatment used in wide areas of medical field, such as urology, cardiology, orthopedics, and physical therapy, among others. It is an alternative for orthopedic ...

ShockWave’s disruptive approach within the calcified cardiovascular disease space creates a first-mover advantage offering the opportunity of robust sales growth. ShockWave Medical’s business model ...

As an adjunct to bypass surgery for ischemic cardiomyopathy, a cardiac shockwave therapy aimed at regenerating ischemic myocardium boosted left ventricular ejection fraction (LVEF) and physical ...

ATLANTA, May 19, 2021 /PRNewswire/ -- SoftWave Tissue Regeneration Technologies patented extracorporeal shock wave device called the OrthGold 100® was cleared by the FDA on May 4, 2021, for the ...

The FDA on Dec. 28 permitted the marketing of Sanuwave’s Dermapace System to treat adults with diabetic foot ulcers. Here are three things to know. 1. The Dermapace System is an external shock wave ...

DUBLIN, Dec. 18, 2020 /PRNewswire/ -- The "Extracorporeal Shockwave Device Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application" report has ...

Shockwave will purchase outstanding Neovasc shares for $27.25 each, valuing the company at around $100 million, according to a Jan. 17 news release from Shockwave. Neovasc specializes in the treatment ...

SANTA CLARA, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified ...

Sanuwave Inc. finally won de novo approval for its Dermapace diabetic foot ulcer treatment technology after years of struggling to get the device to the U.S. market. The Alpharetta, Ga.-based ...

ANN ARBOR, MI / ACCESSWIRE / July 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products ...